Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III.
(33/85)
PURPOSE: To evaluate the efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation (RAP) stages II and III. METHODS: A retrospective, interventional, nonrandomized multicentric study was performed. The files, optical coherence tomography (OCT) scans, indocyanine green, and fluorescein angiograms of patients with RAP stages II and III who had been treated by intravitreal bevacizumab were retrospectively examined. Final visual acuity, number of injections, and appearance of adverse events were considered as main outcome indicators. RESULTS: Twenty-six eyes from 24 patients (9 male and 15 female) were treated by intravitreal bevacizumab. Fourteen eyes presented RAP stage II and 12 eyes presented RAP stage III. Mean age was 76+/-9 and 79+/-6 years, respectively. Mean initial best-corrected visual acuity (BCVA) was logMAR 0.60+/-0.24 and 1.13+/-0.37, respectively. Mean BCVA was 0.62+/-0.26 and 1.06+/-0.37, respectively, at 6 months (p=0.96 and 0.10, respectively, Student t test for paired data) and 0.63+/-0.26 and 1.04+/-0.37, respectively, at 12 months (p=0.82 and p=0.06, respectively, Student t test for paired data). The average number of injections during the first year was 3.4 and 3.2, respectively. CONCLUSIONS: Intravitreal bevacizumab may stabilize visual acuity during the first year in RAP lesion stage II and III. Visual prognosis seems to be better in RAP II lesions. (+info)
The many faces of intraosseous haemangioma: a diagnostic headache.
(34/85)
Intraosseous haemangioma constitutes less than ten percent of all primary bone neoplasms. Approximately 75 percent occur in the calvarium or vertebrae, with long bones, short tubular bones and ribs constituting the rest. We describe a 52-year-old woman who presented with left knee pain for 4-5 years and loss of weight over one week. An initial radiograph of the knee showed several well circumscribed isodense lesions with sclerotic rims in the medullary cavity of the distal femur and diaphysis of the left tibia. There were also lucent lesions with a slightly sclerotic rim in the diaphysis of the left tibia and proximal left fibula. In view of the clinical presentation and radiological findings, extensive investigations were made to rule out metastases and multiple myeloma. An open biopsy with segmental osteotomy of the left mid fibular lesion revealed an intraosseous haemangioma. (+info)
A 65 Year-old man with an episode of absence attacks and mild mental changes was admitted to the clinic. A skull X-ray film demonstrated a mild spotty calcification in the left frontal region. The lesion was recognized as a heterogeneous high density and irregular round egg-sized tumor on computerized tomography and appeared as an avascular mass with cerebral angiography. The patient also had abnormal low-intensity spots that were widely scattered in the supratentorial, parieto-temporal cortex, cerebellum and the pons on MRI (gradient-field echo method). Abdominal echography demonstrated a single tumor shadow in the liver. Only the frontal lesion removed and histological examination confirmed the diagnosis of a cavernous angioma. The scattered low density lesions observed with the MRI (both T1 and T2 weighted) were also indicative of a cavernous angioma. These lesions were probably caused by hemosiderin at different phases of chemical breakdown. The cases of multiple cavernous angiomas reported by McCormick and Rubinstein had a similar appearance with a spot-shaped hemorrhage or angioma. Many other reports of multiple lesions will probably appear in the future with the use of MR, since a small cavernous angioma can be easily visualized by gradient-field echo method. (+info)
Sclerosing angiomatoid nodular transformation of the spleen: CT, MR, PET, and (9)(9)(m)Tc-sulfur colloid SPECT CT findings with gross and histopathological correlation.
(36/85)
The impact of advances in molecular genetic pathology on the classification, diagnosis and treatment of selected soft tissue tumors of the head and neck.
(37/85)